C91.Z2
BillableOther lymphoid leukemia, in relapse
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C91.Z2 an HCC code?
Yes. C91.Z2 maps to Colorectal, Bladder, and Other Cancers under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C91.Z2
For C91.Z2 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C91.Z2 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C91.Z2 is the ICD-10-CM diagnosis code for other lymphoid leukemia, in relapse. This code describes a type of blood cancer called lymphoid leukemia that has returned after a period of remission or improvement. The patient's cancer cells have come back and are actively growing again. C91.Z2 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C91.Z2 maps to Colorectal, Bladder, and Other Cancers (HCC 22) with a community, non-dual, aged base RAF weight of 0.000. Under the older CMS-HCC V24 model, C91.Z2 maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Ensure documentation clearly states the leukemia is in 'relapse' or 'recurrence' before assigning this code; remission status must be explicitly documented. Because C91.Z2 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C91.Z2 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Ensure documentation clearly states the leukemia is in 'relapse' or 'recurrence' before assigning this code; remission status must be explicitly documented
- •Verify the specific type of lymphoid leukemia (chronic lymphocytic, acute lymphoblastic, etc.) is documented, as other more specific C91 codes may be more appropriate than the unspecified 'Z2' category
Clinical Significance
Other lymphoid leukemia in relapse indicates recurrence of a specified but uncommon lymphoid leukemia after prior remission. Relapse in rare lymphoid leukemia subtypes poses unique clinical challenges due to limited published treatment data and fewer established salvage protocols. These patients may benefit from referral to specialized centers with experience in rare hematologic malignancies.
Documentation Requirements
- ✓Documentation must confirm the specific subtype, prior remission, and current evidence of disease recurrence.
- ✓Updated diagnostic studies at relapse should be documented, including immunophenotyping and molecular/cytogenetic testing.
- ✓The interval between remission and relapse, prior treatment history, and salvage treatment plan should be recorded.
- ✓Consider clinical trial enrollment and document candidacy assessment.